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Introduction
Flow-induced shear stress plays a central role on endothelial re-
sponse and mechano-signal transduction in the cardiovascular sys-
tem. The mechanical shear force stimulates endothelial protein ac-
Original Article
http://dx.doi.org/10.4070/kcj.2014.44.2.105
Print ISSN 1738-5520 • On-line ISSN 1738-5555
Nitric Oxide Synthase Inhibition Attenuates Cardiac Response  
to Hemodilution with Viscogenic Plasma Expander
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Background and Objectives: Increased vascular wall shear stress by elevated plasma viscosity significantly enhances the endothelial ni-
tric oxide synthase (eNOS) activity during an acute isovolemic hemodilution. Also the modulation of plasma viscosity has effects on the car-
diac function that were revealed if a left ventricular (LV) pressure-volume (PV) measurement was used. The aim of this study was to assess 
cardiac function responses to nitric oxide synthase (NOS) inhibitors with the presence of an elevated plasma viscosity but a low hematocrit 
level. Furthermore, systemic parameters were monitored in a murine model.
Materials and Methods: As test group five anesthetized hamsters were administered with N(G)-nitro-L-arginine methyl ester (L-NAME), 
NOS inhibitor, whereas five other hamsters were used as control group without L-NAME infusion. The dosage of L-NAME was 10 mg/kg. An 
isovolemic hemodilution was performed by 40% of estimated blood volume with 6% w/v dextran 2000 kDa, high viscosity plasma expanders 
(PEs) with viscosity 6.34 cP. LV function was measured and assessed using a 1.4 Fr PV conductance catheter.
Results: The study results demonstrated that NOS inhibition prevented the normal cardiac adaptive response after hemodilution. The end-
systolic pressure increased 14% after L-NAME infusion and maintained higher than at the baseline after hemodilution, whereas it gradually 
decreased in the animals without L-NAME infusion. The admission of L-NAME significantly decreased the maximum rate of ventricular 
pressure rise (+dP/dtmax), stroke volume and cardiac output after hemodilution if compared to the control group (p<0.05). 
Conclusion: This finding supports the presumption that nitric oxide induced by an increased plasma viscosity with the use of a high viscosity 
PE plays a major role in the cardiac function during an acute isovolemic hemodilution. (Korean Circ J 2014;44(2):105-112)
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tivities including nitric oxide synthesis (NOS) by endothelial nitric 
oxide synthase (eNOS).1)2) Nitric oxide (NO) is an important mediator 
that has various physiological functions such as vascular tone reg-
ulation, platelet activation prevention, vascular smooth muscle pro-
liferation inhibition and myocardial contractility regulation.3-5) The 
inhibition of eNOS activity and endothelial dysfunction decreases 
the inotropic effect of ventricular myocytes and constricts blood 
vessels in a normal physiological range of hematocrit (Hct).6) Fur-
thermore, the injection of N(G)-nitro-L-arginine methyl ester (L-NAME) 
or other NOS inhibitors induces high blood pressure and increases 
microvascular resistance to blood flow.7-9)
Vascular wall shear stress (WSS) is modulated by blood flow and 
blood viscosity. A previous study in the cremaster muscles of ham-
sters using dextran with different molecular weights as an exchange 
solution showed that elevated plasma viscosity increased WSS and 
produced vasodilation.10) Similarly, Tsai et al.11) demonstrated that 
elevated plasma viscosity increased perivascular NO production in 
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concert with the increased aortic eNOS protein expression during 
extreme hemodilution. Studies in awake animals treated with high 
viscosity plasma expanders (HVPEs) showed advantageous effects in 
the microvascular function in both hemorrhagic shock-resuscita-
tion and acute extreme hemodilution models.12-14) These studies re-
vealed that an elevated plasma viscosity positively correlates with 
increased WSS and NOS. The vascular network connected with the 
heart is a complex biological coupling. Therefore, the effects of in-
creased plasma viscosity by plasma expanders (PEs) on the circula-
tory system are being continually investigated in order to gain a 
better understanding related to novel PE development. Recently, us-
ing a miniature pressure-volume (PV) conductance catheter in an 
acute hemodilution, it was found that HVPE provides better effects 
on cardiac function compared with low viscosity plasma expanders 
(LVPE).15) Furthermore, a recent study has demonstrated that animals 
hemodiluted with LVPE combined with a proper amount of NO do-
nor had positive effects on cardiac function, which could not be 
observed in animals hemodiluted with LVPE only.16) The aim of this 
study was to assess the response of cardiac function to NOS inhibi-
tors during an elevated plasma viscosity but with low Hct level.
Materials and Methods 
Animal preparation 
The experiments were carried out in anesthetized male Golden 
Syrian hamsters with a weight between 60 and 70 g (Charles River 
Laboratories; Boston, MA, USA). The animal handling and care fol-
lowed the NIH Guideline for Care and Use of Laboratory Animals. 
The experimental study was approved by the animal care commit-
tee of the University of California, San Diego. Animal surgery was 
performed following an intraperitoneal (i.p.) administration of so-
dium pentobarbital (50 mg/kg). The left jugular vein was cannulat-
ed to allow infusion fluid and the left femoral artery was catheter-
ized for systemic blood pressure monitoring and blood withdrawal 
and sampling. In addition, a tracheotomy was conducted and the 
animal was cannulated with a polyethylene-90 tube to facilitate 
spontaneous breathing. The body core temperature was maintained 
at around 37°C by being placed in the supine position on a heating 
pad. During the experiment, if the animals responded to a toe 
pinching, a small bolus of sodium pentobarbital (10–15 mg/kg, i.p.) 
was administered for maintaining an anesthesia condition. 
Inclusion criteria
Animals under anesthesia were included in the experiments if 
they had no signs of bleeding and their systemic parameters were 
within the normal range: 1) mean arterial pressure (MAP) above 80 
mm Hg, 2) heart rate (HR) above 320 beats/minute, and 3) systemic 
Hct level above 45%. 
Moderate isovolemic hemodilution protocol
An isovolemic hemodilution was performed using PE consisting 
of a solution of Dextran 6% T2000 (Pharmacosmos, Holbaek, Den-
mark) in 0.9% sodium chloride mixed with 10% human serum albu-
min. This procedure has been reported elsewhere, briefly, forty per-
cent (40%) of the animals blood volume (BV) estimated as 7% of 
body weight was withdrawn from the femoral artery catheter using 
a dual syringe pump (33 syringe pump, Harvard Apparatus, Hollis-
ton, MA, USA) at a rate of 100 µL/min.17) Simultaneously, PE was 
administered into the jugular vein catheter at the same rate to 
lower the systemic Hct to about 20%. The experimental protocol is 
schematically shown in Fig. 1. The animals were monitored for 1 hour 
after the completion of the hemodilution. At the end of experiment, 
blood samples were collected to measure plasma viscosity, plasma 
colloid osmotic pressure (COP) and blood conductance. The PE solu-
tion had a viscosity of 6.3 cP and 43 mm Hg in COP.
Experimental groups
Ten animals were entered into the study and randomly assigned 
to two groups. Animals in the first group (n=5) underwent hemodi-
lution with only the PE (Control Group). Animals in the second group 
(n=5) were administered with 10 mg/kg of L-NAME (i.v.) 20 minutes 
before being hemodiluted with the PE (Treated Group). This dose of 
L-NAME was a low dose as reported by Sakai et al.8)
Systemic parameters and biophysical properties
The MAP was continuously monitored using a fluid-filled pressure 
transducer and a signal acquisition system (MP150, Biopac System 
Inc., Santa Barbara, CA, USA). The systemic Hct level was determined 
from arterial blood samples taken in heparinized capillary tubes and 
centrifuged. Viscosity was measured at a shear rate of 160s-1 using 
a cone and plate viscometer (Brookfield Engineering Laboratories, 
Middleboro, MA, USA). The COP of PE and blood plasma was mea-
sured using a membrane colloid osmometer (model 420, Wescor, Lo-
gan, UT, USA).
Fig. 1. Schematic diagram of acute isovolemic hemodilution protocol for 
animals treated with L-NAME. BL: baseline, TM: treatment, HD15: hemodilu-
tion 15 minutes, HD30: hemodilution 30 minutes, HD60: hemodilution 60 
minutes, L-NAME: N(G)-nitro-L-arginine methyl ester.
Stabilization Treatment Hemodilution
HD60HD30HD15TMBL
20 minutes 20 minutes
L-NAME
infusion
Exchange
40% blood volume
60 minutes
107Surapong Chatpun, et al.
http://dx.doi.org/10.4070/kcj.2014.44.2.105www.e-kcj.org
Cardiac function
The closed-chest method was used to assess cardiac function.18) 
Briefly, the right common carotid artery was exposed allowing to 
insert a 1.4 Fr PV conductance catheter (PV catheter; SPR-839, Mil-
lar Instruments, Houston, TX, USA). The PV catheter was advanced 
passing through the aortic valve into the left ventricle. At baseline 
conditions and the end of the experiment, a small bolus (10 µL) of 
15% hypertonic saline was administered intravenously to deter-
mine the parallel volume. The left ventricular (LV) pressure and 
volume measurements were digitized and acquired at 1 kHz sam-
pling rate (MPVS300, Millar Instruments, Houston, TX, USA and 
PowerLab 8/30, ADInstruments, Colorado Springs, CO, USA). Then 
the cardiac function data was analyzed with PVAN software (ver-
sion 3.6, Millar Instruments, Houston, TX, USA). The selected 8-12 
cardiac cycles were analyzed for cardiac function indices at each 
time point.
Estimation of left ventricular blood volume 
The LV BV was measured in conductance units (relative volume 
unit) and converted to actual BV (μL) using a known-volume cu-
vette at the end of the experiment. The blood conductance at base-
line was estimated from the baseline Hct level, using the pooling 
data of blood conductance and Hct relationship.17)
Statistical analysis
The results are depicted as mean±standard deviation. The data 
pertaining to the same group were evaluated using the analysis of 
variance and Dunnett’s multiple comparison test for post hoc analy-
ses. An unpaired, two-tailed t-test was performed to compare be-
tween groups at each time point. 
Fig. 2. Mean arterial blood pressure (MAP) (A) and heart rate (HR) (B) measured at baseline (BL), after N(G)-nitro-L-arginine methyl ester treatment (TM), 
at 0, 15, 30, and 60 minutes after hemodilution (HD). *p<0.05 compared to BL, †p<0.05 compared between groups.
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Table 1. Systemic parameters and pressured related cardiac function measured at BL, after L-NAME TM, at 15, 30, and 60 minutes after HD
Parameter Group BL TM HD15 HD30 HD60
MAP (mm Hg) Control 97±6 - 88±6* 86±9* 81±7*
Treated 88±6 114±7* 102±8† 95±12 80±14
HR (bpm) Control 471±20 - 463±26 449±34 447±28
Treated 441±41 414±39 363±33*† 362±29*† 355±27*†
Hct (%) Control 53±2 - - - 27±2*
Treated 53±4 - - - 25±2*
Pes (mm Hg) Control 118±7 - 110±7 109±11 106±11
Treated 110±9 138±10* 133±11*† 123±13* 116±9*
Ped (mm Hg) Control 8±4 - 9±4 8±2 8±2
Treated 6±2 6±1 9±2* 9±2* 11±4*
+dP/dt (×103 mm Hg/s) Control 12.8±1.3 - 11.6±2.0 11.7±2.7 12.2±1.6
Treated 14.1±1.9 12.9±3.7 10.9±2.3 11.5±2.0 8.8±2.4*
-dP/dt (×103 mm Hg/s) Control -13.7±1.4 - -11.5±1.5 -11.0±1.8 -9.1±1.8*
Treated -8.8±0.9 -11.3±2.2 -10.4±1.8 -10.7±1.9 -8.9±1.7
*p<0.05 compared to baseline, †p<0.05 compared between groups. BL: baseline, L-NAME: N(G)-nitro-L-arginine methyl ester, TM: treatment, HD: hemodi-
lution, MAP: mean arterial pressure, Hct: hematocrit, Pes: end-systolic pressure, Ped: end-diastolic pressure 
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All of the statistics were performed using GraphPad Prism 5.04 
(GraphPad Software, San Diego, CA, USA). Statistical significance 
was determined at a p<0.05.
Results
Systemic parameters
The MAP (Fig. 2A) increased 30% from baseline to 20 minutes 
after L-NAME administration. The effect was long lasting, for at least 
30 minutes after hemodilution, and returned closer to baseline levels 
at 60 minutes after hemodilution. In contrast, the MAP in the con-
trol group was at all points significantly lower after hemodilution 
than at baseline and was significantly lower than in the treated 
group where it was only at time point 15 minutes after hemodilu-
tion. The HRs (Fig. 2B) in the treated group decreased by 15% from 
the baseline, mainly after hemodilution. In the control group, the 
HR remained near baseline values after hemodilution. The systemic 
Hct level decreased from 53±2% to 27±2% and 53±4% to 25±2% 
in the control group and the L-NAME-treated group, respectively. 
Table 1 summarizes the systematic parameters in each group at the 
different time points. Blood viscosity in the control group after he-
modilution was 3.61±0.24 cP whereas plasma viscosity was 2.12± 
0.10 cP. These viscosities were not significantly different compared 
to that of the treated group. 
Cardiac performance
Fig. 3A shows the end-systolic pressure (Pes) and end-diastolic 
pressure (Ped) at baseline and 15 minutes and 60 minutes after he-
modilution, Pes significantly increased after L-NAME injection (25% 
higher than the baseline) and remained higher after hemodilution 
compared to the baseline, whereas Ped did not change after L-
NAME injection. For the control group Pes was significantly lower 
than baseline for all times after hemodilution; Ped remained around 
baseline values. Fig. 3B shows an example of LV pressure and vol-
ume curves for the control group and the treated group at three 
time points of interest (baseline, 15 minutes and 60 minutes after 
hemodilution). There was no difference between both groups for 
both LV pressure and volume at baseline. Animals treated with L-
Fig. 3. Left ventricular (LV) end-systolic pressure (Pes) and LV end-diastolic pressure (Ped) measured at baseline (BL), after N(G)-nitro-L-arginine methyl ester 
(L-NAME) treatment (TM), at 15, 30, and 60 minutes after hemodilution (HD) (A). Example of LV pressure and volume waveforms at BL, after L-NAME TM and 
at 60 minutes after HD (B). Maximum rate of pressure rise (+dP/dtmax) (C) and Maximum rate of pressure fall (-dP/dtmax) (B) recorded at BL, after L-NAME TM, 
at 15, 30, and 60 minutes after HD. Values are relative to baseline and presented as mean±SD. *p<0.05 compared to BL, †p<0.05 compared between groups.
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NAME had a higher LV pressure than the animals hemodiluted with 
HVPE only, especially at 15 minutes after hemodilution. Fig. 3C 
shows the maximum and minimum rates of pressure change (dP/dt) 
for the same points of interests. The maximum rate of pressure rise 
(+dP/dtmax) decreased after hemodilution in both groups when com-
pared to the baseline. In the L-NAME treated group, +dP/dtmax was 
significantly lower than in the control group where it was only 60 
minutes after hemodilution. As shown in Fig. 3C, the maximum rate 
of pressure fall (-dP/dtmax) in the L-NAME group was significantly 
higher than in the control group (p<0.05) for every time point after 
hemodilution. These parameters were also summarized in Table 1 at 
the time points of interest.
Fig. 4 shows the cardiac function indices for the control and treat-
ed groups. Cardiac output (CO) was significantly decreased in the 
treated group after L-NAME injection at all-time points compared to 
both, baseline and control group. Stroke volume (SV) was signifi-
cantly decreased after hemodilution compared to the control group, 
but remained without significant changes compared to baseline. 
Stroke work (SW) remained with no significant changes between 
groups and relative to baseline up to 15 minutes after hemodilution. 
However, it was significantly increased in the control group at 30 
minutes and 60 minutes after hemodilution, at this last time point 
it was significantly higher (p<0.05) for the control group compared 
to the treated group. The ejection fraction was not statistically dif-
ferent between groups or compared to baseline. However, it exhibit-
ed a trend to decrease (by 14%) in the treated group after L-NAME 
injection and to increase in the control group during hemodilution. 
Fig. 5. Systemic vascular resistance (SVR) at baseline (BL), after N(G)-nitro-
L-arginine methyl ester treatment (TM), at 15, 30, and 60 minutes after he-
modilution (HD). Values are relative to BL and presented as mean±SD. 
*p<0.05 compared to BL, †p<0.05 compared between groups.
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As L-NAME significantly increased MAP and reduced CO, the 
treated group presented a higher systemic vascular resistance (SVR) 
compared to the control group (p<0.05) as presented in Fig. 5. The 
SVR in the treated group was significantly higher than at the base-
line (by 35%), whereas SVR in the control group dropped 32% be-
low the baseline (p<0.05) after hemodilution. Fig. 6 illustrates ex-
amples of PV loops during the period of the experiment (baseline, 
after L-NAME administration and 15 minutes after hemodilution). 
The PV loop in the control group shifted to the right after hemodi-
lution, indicating an increase in cardiac preload. In contrast, the PV 
loops in the L-NAME group did not show any right shift, but there 
was an apparent increase in Pes due to the effect of L-NAME. 
Discussion
This study demonstrated that eNOS inhibition prevents the nor-
mal cardiac adaptive response after anemic states. Using HVPE in 
an isovolemic hemodilution to elevate plasma viscosity provided a 
positive cardiac adaptation to the lowered oxygen carrying capacity 
of blood, but the eNOS inhibition reflected negative effects on the 
load dependent cardiac indices after hemodilution. This study sup-
ports the view that NO production plays an important role in the 
regulation of cardiac performance during hemodilution when in-
duced by shear stress on endothelium from elevated plasma vis-
cosity. 
In previous studies, it was demonstrated that the PE viscosity 
plays a major role in the maintenance of microcirculatory function 
and cardiac performance during anemic states.13)15) In this study, 
however, it was shown that the positive effects of HVPE use are 
weakened by the inhibition of eNOS. This effect may be explained 
by the relationship between endothelial WSS and the endothelial 
mediated NO production which is similar to the work demonstrat-
ed by Tsai et al.11) In normal conditions, the production of NO by the 
endothelium is mediated by WSS.
In the present study, before hemodilution, both high mean arteri-
al blood pressure and high Pes were clearly observed in animals in-
travenously injected with L-NAME, indicating there was an increase 
in afterload. During the first 30 minutes after L-NAME infusion, it 
was observed that L-NAME caused a significant change in mean ar-
terial blood pressure due to vasoconstriction induced by the eNOS-
inhibitory effect of L-NAME. However, this effect was not prolong-
ing. Furthermore, the SVR after L-NAME administration significantly 
increased, causing the heart to increase pumping pressure to over-
come this resistance, and remained higher than the baseline even 
after hemodilution. Similarly, Sakai et al.8) observed that the inhibi-
tion of NOS activities by L-NAME induced systemic hypertension, 
constriction of resistant arteries and reduction of microvascular 
blood flow. Furthermore, several previous studies have shown that 
the inhibition of NOS causes coronary vasoconstriction in both iso-
lated hearts and conscious animals.19-21) The NOS inhibitors are gua-
nidino amino acids, which compete with binding molecules at the 
NOS active site. L-NAME is a non-selective NOS inhibitor, which can 
inhibit the constitutive isoform of NOS, including eNOS. Therefore, 
this inhibition can negatively affect the vascular tone regulation. Al-
though animals treated with L-NAME were hemodiluted with HVPE, 
the mean arterial blood pressure as well as the Pes was higher com-
pared with those of animals without treatment and hemodiluted 
with HVPE. This indicates that induced-shear stress NO can not be 
produced, leading to a vasoconstrictive effect in the animals treated 
with L-NAME. 
Animals with L-NAME treatment showed a significant simulta-
neous decrease in the HR after L-NAME infusion. As treated ani-
mals were hemodiluted with HVPE, a continuous drop in HR was 
observed. In contrast, animals without L-NAME treatment, demon-
Fig. 6. Examples of pressure-volume loops in the control group and the L-NAME-treated group at baseline (BL), after L-NAME treatment (TM) and at 15 
minutes after hemodilution (HD15). LV: left ventricular, L-NAME: N(G)-nitro-L-arginine methyl ester.
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strated a slight decrease in HR after hemodilution. With the study 
by Pabla and Curtis20) on the effects of NO modulation on cardiac 
arrhythmias in isolated rat hearts it was reported that L-NAME caused 
sinus bradycardia–similar to the results of other in vivo studies re-
porting on the bradycardia effects of NOS.22)23) Recently, NO donor 
administration in animals hemodiluted with Dextran 70 kDa demon-
strated the chronological effect of a 4% increase in the HR from the 
baseline, which was significantly increased when compared to ani-
mals without NO donor administration.16) In addition, Bryan et al.24) 
have reported the effects on hemodynamics in a normal Hct level, 
that the pre-administration of S-nitro-N-acetylpenicillamine fol-
lowed by L-NAME administration and vice versa can decrease sys-
tolic blood pressure and mean arterial blood pressure, while the 
HR is increased.25) These previous studies emphasize the role of NO 
on HR. Therefore, it is important to note that the inhibition of NOS 
or the decrease in NO production coupled with hemodilution with 
HVPE can cause a negative effect on HR. However, controversial and 
unclear issues related to the chronological effects of NO still remain, 
especially in in vivo studies.26) 
In the present study, the CO markedly decreased after L-NAME 
infusion followed by hemodilution with HVPE, while CO in the group 
without L-NAME treatment significantly increased from the base-
line. This finding is in agreement with those of several studies, which 
have indicated that L-NAME decreases the CO in a normal level of Hct 
either in the short-term or long-term treatments with L-NAME.25)27)28) 
Furthermore, in this study, the L-NAME administration led to a re-
duction in SV even after hemodilution. Especially at 15 minutes after 
hemodilution as shown by PV loops, it could be noticed that the 
end-diastolic volume decreased after hemodilution in animals with 
L-NAME treatment which led to lower SV. Generally, there is a com-
pensatory mechanism for a reduction in oxygen transport capabil-
ity–i.e., hemodilution by an increase in CO via either an increase in 
HR or an enhancement of SV. This compensation was still observed 
after hemodilution in animals without L-NAME treatment but not 
in animals treated with L-NAME. By administration through a cor-
onary catheter, using non-selective NOS inhibitors such as N-nitro-
L-arginine (L-NNA) in normal dogs an increment in the coronary 
blood flow was shown.29) In contrast, Biwer et al.28) demonstrated 
that long-term L-NAME-treated rats had not only a decrease in CO 
and SW but also a decrease in coronary blood flow, which potential-
ly caused cardiac dysfunction. Therefore, it is a point of concern that 
using PEs in hemodilution with a stage of NOS impairment can lead 
to an attenuation of the cardiac compensatory mechanism. 
The use of a non-selective NOS inhibitor, L-NNA, resulted in an in-
crease in myocardium oxygen consumption in normal un-anesthe-
tized dogs, whereas using L-NAME in anesthetized open-chest dogs 
did not present this.29)30) In the present study, after hemodilution 
with HVPE, animals treated with L-NAME presented a lower SW and 
+dP/dtmax than animals without L-NAME treatment. This indicates an 
attenuation of energy to pump out blood from the chamber. How-
ever, this attenuation of energy related to a decrease in SV and a 
smaller PV loop area. Therefore, it can be pointed out that an impair-
ment of NOS significantly affects cardiac load-dependent indices 
after hemodilution. Also the heart seems to be less able to adjust to 
the change of reduced Hct content in animals treated with L-NAME. 
The analogs of L-arginine were used to treat some patient’s con-
ditions such as hypotension during septic shock. As a result of the 
presented study, it was demonstrated that the cardiac compensa-
tory mechanism attenuated by L-NAME responded to hemodilu-
tion. Therefore, it might not be beneficial to administer L-NAME in 
patients with low Hct and septic shock or with a required hemodi-
lution regarding to the modalities of sepsis treatment. On the oth-
er hand, for septic patients with L-NAME administration a high vis-
cosity PE might not be suitable for volume replacement. However, in 
the present study L-NAME administration was performed as a 
short-term treatment and therefore it is necessary to look at long-
term treatment effects on a hemodiluted condition. Furthermore, 
the study had several limiting issues such as a small number of ani-
mals in each group, only two dosages of L-NAME, no oxygen de-
livery assessment and the effects of anesthetics (sodium pentobar-
bital) as a cardiac depressor.
In conclusion, it was shown that eNOS inhibition prevents the 
normal cardiac adaptive response after anemic states. Using high 
viscogenic PE in isovolemic hemodilution to elevate plasma viscos-
ity provided a positive cardiac adaptation to the lowered oxygen 
carrying capacity of blood, but eNOS inhibition reflected negative ef-
fects on load dependent cardiac indices. 
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